Research Progress on the Risk Factors for the Transition from Mild Cognitive Impairment to Alzheimer's Disease
Abstract
China has entered an aging society, and Alzheimer’s disease is one of the leading causes of death among the elderly. Mild cognitive impairment is a critical transitional stage between normal cognitive function and dementia. The progression of MCI to AD has become a key scientific issue. This review summa - rizes the latest research progress on the risk factors for the transition from MCI to AD. It can provide targets for early clinical screening, assessment, and treatment of the disease, and offer a basis for delaying disease progression and improving treatment outcomes. This research is of great significance for deepening studies in this field and reducing the social and emotional burden as well as the health - care burden.Copyright (c) 2025 han luo
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. James T, Mukadam N, Sommerlad A, et al. Protection against discrimination in national dementia guideline recommendations: A systematic review. PLoS Med. 2022, 19(1): e1003860.[2] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021, 397(10284): 1577-1590.[3] Jia J, Wei C, Chen S, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018, 14(4): 483-491.[4] Fan Y, Gao Y, Therriault J, et al. The Effects of CSF Neurogranin and APOE ε4 on Cognition and Neuropathol-ogy in Mild Cognitive Impairment and Alzheimer’s Disease. Front Aging Neurosci. 2021, 13: 667899.[5] Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018, 14(4): 535-62.[6] Jin D, Zhou B, Han Y, et al. Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Bio-markers for Alzheimer’s Disease. Adv Sci (Weinh). 2020, 7(14): 2000675.[7] Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. Jama. 2014, 312(23): 2551-2561.[8] Chen H, Sheng X, Luo C, et al. The compensatory phenomenon of the functional connectome related to patho-logical biomarkers in individuals with subjective cognitive decline. Transl Neurodegener. 2020, 9(1): 21.[9] Park JE, Gunasekaran TI, Cho YH, et al. Diagnostic Blood Biomarkers in Alzheimer’s Disease. Biomedicines. 2022, 10(1): 169.[10] Chen Y, Qian X, Zhang Y, et al. Prediction Models for Conversion From Mild Cognitive Impairment to Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2022, 14: 840386.[11] Kim DH, Oh M, Kim JS. Prediction of Conversion from Mild Cognitive Impairment to Alzheimer’s Disease Using Amyloid PET and Brain MR Imaging Data: A 48-Month Follow-Up Analysis of the Alzheimer’s Disease Neuro-imaging Initiative Cohort. Diagnostics (Basel). 2023, 13(21): 205-215.[12] Shigemizu D, Akiyama S, Higaki S, et al. Prognosis prediction model for conversion from mild cognitive im-pairment to Alzheimer’s disease created by integrative analysis of multi-omics data. Alzheimers Res Ther. 2020, 12(1): 145.[13] Vemuri P, Lesnick TG, Przybelski SA, et al. Age, vascular health, and Alzheimer disease biomarkers in an el-derly sample. Ann Neurol. 2017, 82(5): 706-718.[14] Inzelberg R, Massarwa M, Schechtman E, et al. Estimating the risk for conversion from mild cognitive im-
